Zobrazeno 1 - 10
of 146
pro vyhledávání: ''
Autor:
Miguel Gil-Gil, José A. García-Sáenz, E Dalmau Portulas, Elena García-Martínez, Nuria Ribelles, A. Santaballa Bertran, E. Martínez de Dueñas, I Alvarez-Lopez, Susana Bezares
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Clinical & Translational Oncology
Universidad de Barcelona
Clinical & Translational Oncology
PurposeHormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on anti-estrogen hormo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63a263cb82f360402dddafab187eefb
http://hdl.handle.net/2445/174389
http://hdl.handle.net/2445/174389
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Liisa M. Pelttari, Paula Poikonen-Saksela, Kristiina Aittomäki, Päivi Auvinen, Arja Jukkola-Vuorinen, Sanna Hallamies, Heli Nevanlinna, Johanna Mattson, Carl Blomqvist, Antti Jekunen
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-5 (2017)
BMC Cancer
BMC Cancer
Background Several susceptibility genes have been established for female breast cancer, of which mutations in BRCA1 and especially in BRCA2 are also known risk factors for male breast cancer (MBC). The role of other breast cancer genes in MBC is less
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4819e7805611ab5361165ecad3b1625
https://erepo.uef.fi/handle/123456789/5171
https://erepo.uef.fi/handle/123456789/5171
Autor:
Cecilia Gelfi, Luigi Minafra, Valentina Bravatà, Rossana Norata, Carmelo Lupo, Massimo Viola, Cristina Messa
Publikováno v:
BMC research notes 5 (2012): 343. doi:10.1186/1756-0500-5-343
info:cnr-pdr/source/autori:Luigi Minafra; Rossana Norata; Valentina Bravatà; Massimo Viola; Carmelo Lupo; Cecilia Gelfi; Cristina Messa./titolo:Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report./doi:10.1186%2F1756-0500-5-343/rivista:BMC research notes/anno:2012/pagina_da:343/pagina_a:/intervallo_pagine:343/volume:5
BMC Research Notes
BMC Research Notes, Vol 5, Iss 1, p 343 (2012)
info:cnr-pdr/source/autori:Luigi Minafra; Rossana Norata; Valentina Bravatà; Massimo Viola; Carmelo Lupo; Cecilia Gelfi; Cristina Messa./titolo:Unmasking epithelial-mesenchymal transition in a breast cancer primary culture: a study report./doi:10.1186%2F1756-0500-5-343/rivista:BMC research notes/anno:2012/pagina_da:343/pagina_a:/intervallo_pagine:343/volume:5
BMC Research Notes
BMC Research Notes, Vol 5, Iss 1, p 343 (2012)
Background Immortalized cancer cell lines are now well-established procedures in biomedicine for a more complete understanding of cellular processes in cancer. However, they are more useful in preparation of fresh tumour tissue, in order to obtain ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::879cc7aa8288ebe6181e5c13b2617698
http://hdl.handle.net/10281/37353
http://hdl.handle.net/10281/37353
Publikováno v:
Breast Cancer Research : BCR
We read with interest the recent article by Roth and colleagues [1] reporting the findings of altered tumorspecific microRNAs (miRNAs) in sera of breast cancer patients. This report further substantiates emerging data suggesting that blood-based miRN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37de41d6ad927b9cb6665402fe5e878
http://hdl.handle.net/10379/11894
http://hdl.handle.net/10379/11894
Autor:
C. Rose, R Leonard, M Tubiana-Hulin, Denis Lacombe, J Vinholes, J Wildiers, J Michel, Robert E. Coleman, J Nortier, J. Ford, F. Mignolet, P Bastit
Publikováno v:
British Journal of Cancer
This study was designed to evaluate new bone resorption and tumour markers as possible alternatives to serial plain radiographs for the assessment of response to treatment. Thirty-seven patients with newly diagnosed bone metastases from breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76f16dd46c0774b038d4bedfedc3bf7f
Publikováno v:
Cancer Immunology, Immunotherapy
To examine the relationship between cytotoxic T lymphocyte antigen 4 (CTLA-4) expression and breast cancer prognosis, CTLA-4 expression was immunohistochemically detected in paraffin-embedded specimens of primary tumors from 130 patients with breast
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background The human Y-box-binding protein 1 (YB-1) is a member of the DNA/RNA-binding family of proteins that regulates transcription and translation of genes. Previous studies suggest that YB-1 may have an oncogenic role in various cancers. In this
Autor:
Pawel Jozwiak, Anna Krzeslak, Hanna Romanowicz, Katarzyna Wójcik-Krowiranda, Ewa Forma, Andrzej Bieńkiewicz, Magdalena Brys
Publikováno v:
Pathology Oncology Research
Cancer cells have accelerated metabolism and high glucose requirements. The up-regulation of specific glucose transporters may represent a key mechanism by which malignant cells may achieve increased glucose uptake to support the high rate of glycoly
Autor:
Sally Tan, Pasi A. Jänne, John J. Wright, Katherine Larrabee, Hao Guo, Eric P. Winer, Sara M. Tolaney, Eliezer M. Van Allen, Elena Ivanova, Ian E. Krop, Beth Overmoyer, William H. Barry, Jane E. Brock, Geoffrey I. Shapiro, Cloud P. Paweletz, Nikhil Wagle
Publikováno v:
Investigational New Drugs
SummaryBackground MET expression and activation appear to be important for initiation and progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests t